PSMA-Targeted siRNA Nanoparticles (Avidity NanoMedicines)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NamePSMA-Targeted siRNA Nanoparticles (Avidity NanoMedicines)
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionAndrogen Receptor degradersProstate-Specific Membrane Antigen modulators
TargetsProstate-Specific Membrane AntigenAndrogen Receptor
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAvidity Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAvidity Biosciences Inc
Active IndicationsN/A
Inactive IndicationsProstatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A